Abstract
Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide. Cytokine-induced killer (CIK) cells are an adoptive immunotherapy reported to have strong anti-tumour activity across a range of cancers. They are a heterogeneous mix of lymphoid cells generated by culturing human peripheral blood mononuclear cells (PBMCs) with cytokines and monoclonal antibodies in vitro. We compared CIK cells from healthy donors and donors with CRC liver metastases, generated in RPMI supplemented with 10% fetal bovine serum (FBS) or three different serum-free media. CIK cells generated in serum free medium X-VIVO 15 were comparable to those from RPMI medium with 10% FBS in terms of the number and percentages of the main subsets of cells in the CIK culture, and the intracellular levels of granzyme B and perforin, and the pro-inflammatory cytokines IL-2, IFN-γ and TNF-α. There was no significant difference in cytotoxicity against CRC cell lines grown in 2D cultures or as spheroids, and against autologous patient-derived tumour organoids. CIK cells from patients with CRC liver metastases grown in X-VIVO 15 media were similar to those from healthy donors in each of the measures. Donor attributes such as age, sex, or prior chemotherapy exposure had no significant impact on CIK cell numbers or function. These results support further investigations into the therapeutic application of autologous CIK cells in the management of patients with CRC liver metastases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a Tour de Cure Early Career Research Grant, an Adelaide Medical School Mature Grant Development Award and Cancer Council SA Beat Cancer Project Grant (K.F.). C.L. was supported by a University of Adelaide Postgraduate Research Scholarship
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Research Ethics Committee of the Central Adelaide Local Health Network gave ethical approval of this work (protocol number HREC/14/TQEHLMH/164).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- Abbreviations
- Definitions
- CAPOX
- Capecitabine and oxaliplatin
- ChRT
- Concurrent chemoradiotherapy
- CO2
- Carbon dioxide
- CIK
- Cytokine-induced killer
- CRC
- Colorectal cancer
- CRLM
- Colorectal cancer liver metastases
- DMEM
- Dulbecco’s Modified Eagle Medium
- DMSO
- Dimethyl sulfoxide
- DNAM-1
- DNAX Accessory Molecule-1
- DPBS
- Dulbecco’s phosphate buffered saline
- EDTA
- Ethylenediaminetetraacetic acid
- FACS
- Fluorescence-activated cell sorting
- FASL
- Fas ligand
- FBS
- Fetal bovine serum
- FOLFOX
- Folinic acid, fluorouracil and oxaliplatin
- GMP
- Good manufacturing practice
- h-EGF
- Human epidermal growth factor
- HEPES
- N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid
- IFN-γ
- Interferon-gamma
- IL-2
- Interleukin-2
- MHC
- Major histocompatibility complex
- N-acetyl-L
- cyst N-acetyl-L-cysteine
- NK
- Natural killer
- NKG2D
- Natural-killer group 2 member D
- PBMC
- Peripheral blood mononuclear cell
- PBS
- Phosphate-buffered saline
- PDTO
- Patient-derived tumour organoid
- Pen-Strep
- Penicillin-streptomycin
- Phenol-red
- Phenolsulfonphthalein-red
- RPMI
- Roswell Park Memorial Institute
- RT
- Radiotherapy
- SFM
- Serum-free media
- TNF-α
- Tumour neurosis factor-alpha
- TNT
- Total-neoadjuvant therapy
- TRAIL
- TNF-related apoptosis-inducing ligand
